Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation

Abstract

ObjectivesTo assess clinical service value of STI point-of-care test (POCT) use in a ‘sample first’ clinical pathway (patients providing samples on arrival at clinic, before clinician consultation). Specific outcomes were: patient acceptability; whether a rapid nucleic acid amplification test (NAAT) for Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) could be used as a POCT in practice; feasibility of non-NAAT POCT implementation for Trichomonas vaginalis (TV) and bacterial vaginosis (BV); impact on patient diagnosis and treatment.MethodsService evaluation in a south London sexual health clinic. Symptomatic female and male patients and sexual contacts of CT/NG-positive individuals provided samples for diagnostic testing on clinic arrival, prior to clinical consultation. Tests included routine culture and microscopy; CT/NG (GeneXpert) NAAT; non-NAAT POCTs for TV and BV.ResultsAll 70 (35 males, 35 females) patients approached participated. The ‘sample first’ pathway was acceptable, with >90% reporting they were happy to give samples on arrival and receive results in the same visit. Non-NAAT POCT results were available for all patients prior to leaving clinic; rapid CT/NG results were available for only 21.4% (15/70; 5 males, 10 females) of patients prior to leaving clinic. Known negative CT/NG results led to two females avoiding presumptive treatment, and one male receiving treatment directed at possible Mycoplasma genitalium infection causing non-gonococcal urethritis. Non-NAAT POCTs detected more positives than routine microscopy (TV 3 vs 2; BV 24 vs 7), resulting in more patients receiving treatment.ConclusionsA ‘sample first’ clinical pathway to enable multiple POCT use was acceptable to patients and feasible in a busy sexual health clinic, but rapid CT/NG processing time was too long to enable POCT use. There is need for further development to improve test processing times to enable POC use of rapid NAATs.

New Bugs and New Drugs: Updates in Clinical Microbiology

“…One study that evaluated the use of point-of-care NAAT testing with a 90-min TAT for gonorrhea and chlamydia in an STI clinic in England found that results were available for only 21.4% of patients while they were in the clinic (45). Patient treatment was modified in 3 of 15 patients with available results, and the patients reported high satisfaction (>90%) with the test-and-treat strategy.…”

Right-Sizing Technology in the Era of Consumer-Driven Health Care

“…Another study looked at the impact of the 90-minute Xpert CT/NG test when sample collection was performed on arrival of the patient, with the intention being that the patients receive their results and treatment as needed during the appointment [8]. Actual wait times were evaluated.…”

Evaluation of a Hydrogel-Based Diagnostic Approach for the Point-of-Care Based Detection of Neisseria gonorrhoeae

“…The development of point-of-care tests (POCTs) for an STI such as gonorrhea is recognized as a vital approach to improve timely diagnosis [ 13 , 14 , 20 , 21 , 22 ]. Although POCTs are commercially available for the diagnosis of N. gonorrhoeae , many of these tests do not fit the ASSURED criteria important for STI diagnosis tests, such as affordability, sensitivity, specificity, user friendliness, robustness, and rapidness [ 13 , 21 ].…”